Mounjaro to become leading drug by sales in obesity, diabetes market: GlobalData, ET HealthWorld
London: Novo Nordisk’s Ozempic (semaglutide) took the weight loss sector by storm in 2023, propelled by strong efficacy and safety data coupled with social media buzz and celebrity endorsements that elevated the drug to mainstream prominence. However, a potential challenger has emerged in the form of Eli Lilly’s Mounjaro (tirzepatide), which secured FDA approval for …